FOLFOX + Cetuximab

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-OXALIPLATIN` `DRUG-LEUCOVORIN` `DRUG-5-FLUOROURACIL` `DRUG-CETUXIMAB`

ID	`REG-FOLFOX-CETUX`
Type	Regimen
Status	reviewed 2026-04-26 \| pending_clinical_signoff
Diseases	None declared
Sources	`SRC-ESMO-COLON-2024` `SRC-NCCN-COLON-2025`

Notes

mCRC 1L for RAS-WT LEFT-sided primary (CALGB-80405 / FIRE-3 / CRYSTAL). Right-sided RAS-WT primaries get bevacizumab preferentially. BRAF V600E precludes anti-EGFR (no benefit). Acneiform rash strongly correlates with response — patient education on skin care critical.

Used By

Handbook Chapters

HB-CRC-METASTATIC-1L - Metastatic colorectal cancer: first-line biomarker reasoning

Indication

IND-CRC-METASTATIC-1L-RAS-WT-LEFT - IND-CRC-METASTATIC-1L-RAS-WT-LEFT
IND-CRC-METASTATIC-2L-EGFRI-RECHALLENGE - IND-CRC-METASTATIC-2L-EGFRI-RECHALLENGE